uantitative ultrasound estimates based on the backscatter coefficient (BSC) have demonstrated the ability to detect and classify disease beyond the capabilities of traditional B-mode imaging. Quantitative ultrasound has been able to differentiate live from apoptotic cells or oncotic cells in vitro with highfrequency ultrasound, 1,2 monitor changes in tissue microstructure due to high-intensity focused ultrasound at high frequencies in a preclinical model, 3 and monitor changes due to chemotherapy clinically at 6 MHz. 4 Tumors have been characterized and differentiated using quantitative ultrasound at high frequencies in preclinical models of thyroid cancer, 5 at high frequencies in clinical applicaLauren A. Wirtzfeld, PhD, Goutam Ghoshal, PhD, Ivan M. Rosado-Mendez, PhD, Kibo Nam, PhD, Yeonjoo Park, MS, Alexander D. Pawlicki, MS, Rita J. Miller, DVM, Douglas G. Simpson, PhD, James A. Zagzebski, PhD, Michael L. Oelze, PhD, Timothy J. Hall, PhD, William D. O'Brien Jr, PhD Received July 17, 2014, 
tions for ocular tumors, 6, 7 and at clinical frequencies in human patients for breast tumors 8 and prostate cancers. 9, 10 Also, the BSC has been proven valuable for diagnosing fatty liver disease clinically 11 and for monitoring physiologic and pharmacologic responses in renal function at clinical frequencies in an animal model. 12, 13 One of the BSC features that is often cited as an advantage is its system independence; ie, the same BSC value for a given tissue can be estimated from any imaging platform. Previous studies have demonstrated system independence of BSC estimates in well-characterized phantoms. [14] [15] [16] [17] These investigations applied single-element imaging systems measuring backscatter levels for strong glass bead scatterer phantoms (1-12 MHz), 14, 15 singleelement imaging systems for probing weakly scattering agar-in-agar phantoms (1-13 MHz), 16 and clinical array imaging systems for estimating BSC for phantoms with glass bead scatterers (1-15 MHz). 17 Parametric estimates based on the BSC have demonstrated the ability to differentiate different types of orthotopic mouse tumors ex vivo (16) (17) (18) (19) (20) (21) (22) (23) (24) , 18 to identify regions of micrometastases within resected lymph nodes clinically (26.5 MHz center), 19 and to identify dominant sources of backscattering in the renal cortex (frequencies covering 2.5-15 MHz). 12, 13, 20, 21 The frequency ranges in these studies cover the range being investigated in this study: namely, from the clinical frequencies to the lower end of the small-animal preclinical imaging frequencies, covering, for example, 1 to 21 MHz.
This study addresses the need for demonstrating that in vivo interlaboratory measurements can be used to distinguish different types of tumors, while being able to obtain consistent BSC results from all systems. Previous studies 22, 23 examined BSC agreement across single-element and clinical imaging systems for an in vivo rodent fibroadenoma model over a frequency range of 1 to 14 MHz. The heterogeneity of the benign fibroadenomas provided a near worst-case scenario to evaluate quantitative ultrasound performance. The study presented herein seeks to expand on this work using clinical and preclinical array imaging systems to test their capability to detect known tissue differences while maintaining good agreement in BSC values across all systems.
Mouse (4T1) and rat (MAT) mammary tumor models were used in a comparative experiment with 3 arraybased ultrasound imaging systems (Siemens, Ultrasonix, and VisualSonics) and 5 different transducers covering a range of frequency bandwidths. Backscatter coefficient agreement between systems was assessed, as well as the ability to differentiate the two tumor types.
Materials and Methods

Animal Models
Mouse and rat orthotopic mammary tumor models were used for a comparison between different tumor types. In the first model, 
Ultrasound Systems
Two clinical and 1 preclinical, array-based ultrasound imaging systems were used to image the same tumors. The clinical systems were an Ultrasonix RP (Ultrasonix Medical Corporation, Richmond, British Columbia, Canada), and a Siemens Acuson S2000 (Siemens Medical Solutions USA, Inc Malvern, PA). The preclinical system was a VisualSonics Vevo2100 (VisualSonics, Inc, Toronto, Ontario, Canada). For each system, the individual transducers used and their nominal center frequencies are summarized in Table 1 .
Animal Handling
Both studies were performed at the Bioacoustics Research Laboratory at the University of Illinois at UrbanaChampaign to enable sequential data collection from each animal with each imaging system. During an experiment, an animal was anesthetized by inhaled isoflurane. Hair over the tumor was first shaved and then depilated. The animal was then placed in a custom-built holder so that only the bottom portion of the animal with the tumor was submerged in a tank of 37°C degassed water. The animal remained in the same location for the duration of scanning by all imaging systems. To acquire echo data from approximately the same location within the tumor, each transducer was mounted in a custom holder attached to a micro-positioning system (Daedal; Parker Hannifin Corporation, Irvine, CA). Each transducer was oriented such that ultrasonic scan lines propagated horizontally in identical vertical scan planes, facilitated by the positioning system. Five parallel slices of echo data were acquired with each transducer, separated by up to 1 mm, depending on the tumor size.
Tumors were scanned with each imaging system in a pseudorandom order to avoid any potential biases that could arise due to the length of time under anesthesia. Total scan time for each tumor was approximately 45 minutes, during when the on-site anesthesia level was carefully monitored by a veterinarian (R.J.M.). After imaging with all the transducers, the animal was removed from the water tank and laid in a prone position while a high-resolution 3-dimensional ultrasonic image was acquired with the Vevo2100 using an MS550S probe (nominal center frequency of 40 MHz) to obtain an accurate total volume estimate of the tumor. After imaging, the animals were euthanized, and the tumors were excised and sent to pathology for diagnosis.
Attenuation
Average linear attenuation coefficients were estimated, in separate experiments, using single-element transducers and an insertion loss technique over the bandwidth used in this study 14 for each of the tumor types. Estimates of 0.40 dB/cmMHz for the 4T1 tumors and 0.71 dB/cm-MHz for the MAT tumors were obtained and used for attenuation compensation in data from the clinical systems.
Backscatter Coefficient
The BSC was calculated for each slice from each transducer using a reference phantom technique. 24 The experimental and processing methods have been recently described in detail. 23 Each image slice was divided into analysis windows to calculate the BSC; sizes of the analysis windows are summarized in Table 2 . The BSC for each slice was then computed as the average across all analysis windows. If the tumor size was less than approximately 3 analysis windows, then for the smaller tumors, a smaller analysis window was used to allow for a reasonable BSC estimate to be made.
Statistical Analysis
Detailed statistical analysis methods are described in the "Appendix."
Results
The imaged tumors were histologically confirmed to be carcinomas (4T1) and adenocarcinomas (MAT). The tumor volumes, measured by segmentation of the 3-dimensional images acquired with the Vevo2100 using onboard software, ranged from 6.3 to 617 mm 3 for the 4T1 tumors and from 12.4 to 3096 mm 3 for the MAT tumors.
Backscatter Coefficient
Overlap in the transducer bandwidths across several transducers allowed for a direct comparison of the results visually when graphed. Figure 1 shows examples of the average BSCs obtained from 4 4T1 (Figure 1 , a-d) and 4 MAT ( Figure 1 , e-h) tumors. The BSCs for the individual slices for the corresponding tumors are included in the "Appendix" (see Figure A1 ) to allow for the variability within a tumor and transducer to be observed. A reduction in the interslice and intertransducer variability is observed with The transducer name, nominal center frequency, and approximate bandwidth over which the data were analyzed are included. For each system, the wavelength, λ, was calculated based on the nominal center frequency and assumed speed of sound of 1540 m/s. 
Statistical Analysis
Additional detailed statistical analysis results and graphs are included in the "Appendix." Figure 2a presents an average spline curve fit to combined data in this study (all transducers, 13 4T1 tumors, and 8 MAT tumors) for the entire frequency range (3-22 MHz). The spline curves used cubic B-spline basis functions with 20 knots. 25 Point-wise 90% confidence intervals are displayed based on 1000 bootstrap samples 26 from the BSC curves; all scans for a given tumor and transducer combination were sampled together to account for potential correlation between scans from the same setup. A separation in the average BSC with increased frequency was observed and correlates with the observed statistically significant differences between MAT and 4T1 tumors in the higher frequency band analyzed. Figure 2b presents the fitted average spline curve restricted to tumors with a computed volume of at least 30 mm 3 (approximate diameter of 3.9 mm), whereas Figure 2c presents the fitted average spline curve using only the data from tumors with volume of at least 70 mm 3 (approximate diameter of 5.1 mm). In each case, pointwise 90% confidence intervals are also displayed. These are based on 1000 bootstrap samples 26 from the BSC curves.
The plots in Figure 2 demonstrate a trend in increasing separation between MAT and 4T1 average BSC spline curves as well as in their confidence intervals as the data are filtered for larger tumor sizes. This trend in the separation may relate to the likelihood of the ultrasonic focal region encompassing more of the tumor as the tumor size increases, thus increasing the likelihood that the scattered signals become more targeted from tumor tissue per se.
Discussion
Both the 4T1 and MAT tumors had a decrease in average BSC values with increased tumor volume, with the larger volumes having less variation across the slices from one transducer and less variation between transducers. At 5 MHz, for example, the BSC for the larger tumors was approximately 10 -4 cm -1 Sr -1 , whereas the smaller tumors had BSC values as high as 10 -2 cm -1 Sr -1 .
The smoothed curves in Figure 2a show increasing separation between tumor types with increased frequency. However, because there was not a clear separation in 90% confidence intervals and because a decrease in the standard deviation (Std; see "Appendix") was observed for larger tumors, 2 new plots were constructed using only those tumors whose volumes were greater than 30 mm 3 ( Figure 2b ; BSCs from 9 4T1 and 6 MAT) and for which their volumes were greater than 70 mm 3 (Figure 2c ; BSCs from 5 4T1 and 6 MAT). The separation between the average BSC curves from the 4T1 and MAT tumors shifted to lower frequencies as the volumes of the tumors increased. There are several factors that likely contributed to this increased BSC separation of tumor types for the larger tumors. First, the range of BSC values decreased with increasing tumor volumes; therefore, limiting the data to the larger tumors also confines the BSCs from individual tumors to lower values. Second, for larger tumors, any effects resulting from inclusion of boundaries, specular reflectors and normal tissue due to the elevational resolution, or limits in segmenting the tumor in plane will likely be lower due to the increased likelihood that the analysis windows would be contained entirely within the tumor boundaries, which would increase the scattered data from tumor tissue per se. For the smallest tumors, the effect of echo signals from outside the tumor would likely contribute to more of the analysis windows. Last, any variations in user outlines would have a great effect in the analyzed tissue. Overall, these summary plots show that with a small increase in tumor volume, the improvements in the separation of the BSC curves between the two tumor types were substantial.
Current clinical imaging systems provide transducers with center frequencies up to 13 MHz for clinical breast imaging. Therefore, the largest separation in differentiating the two types of tumors in this study that is observed above 15 MHz is typically beyond the range used for clinical breast imaging. However, when the analysis was confined to tumors greater than 30 mm 3 (corresponding to ≥4 mm in diameter), the BSC began to separate around 10 MHz: that is, within the clinically achievable range.
Although the rodent mammary tumor models used in this study offer a more uniform and simplified tumor architecture compared to the wide variety of tumors encountered clinically, the study demonstrates the level of consistency in making the BSC estimates that is essential for use clinically. Additionally, the ability to begin to differentiate the BSC between these two tumors, which differ subtly from each other, offers the promise of being able to use the BSC to characterize differences in tumor types and, potentially, grades.
Despite the differences in analysis window sizes, system architecture, and transducer characteristics, it was possible to maintain good agreement (no detectable differences between transducers by function analysis of variance (ANOVA) analyses; see "Appendix") between the BSCs from a tumor type for all systems and transducers. This finding suggests that the BSC is a robust estimate and not sensitive to specific analysis parameters when they are properly taken into account during the analysis.
In conclusion, for a given tumor, it was found that different systems and transducers covering the same frequency range yielded similar BSC-versus-frequency results, in support of BSC system independence. Conversely, comparisons of MAT versus 4T1 tumor BSC-versus-frequency curves within imaging systems indicated that statistically significant tumor differences were detected, supporting the power of the approach for potential diagnostic use. Furthermore, combined analysis of all BSC data across frequencies revealed stronger separation between these two tumor types at the higher frequencies. For the MAT and 4T1 tumor models, better BSC detection of the tumor differences occurred at higher frequencies and for larger tumor volumes. Analysis of the dependence on tumor size suggests that the higher frequencies can separate smaller tumor types more effectively than can the lower frequencies. With larger tumors, even at lower frequencies, BSC results were able to separate the two tumor types effectively, suggesting that the resolution volume versus region of interest size is a critical component of the effectiveness of BSC-based classification of regions of interest.
Appendix
Backscatter Coefficient Figure A1 shows the BSCs for the individual slices of the corresponding tumors to allow for the variability within a tumor and transducer to be observed.
Statistical Analysis Methods
To compare the BSC variations across the 5 parallel slices of echo data acquired for a single imaging transducer, the Std of the BSC as a function of frequency was calculated. An average of the Std values across all frequencies was calculated. The Std as a function of tumor volume was plotted to evaluate the repeatability of measurements for different-sized tumors. It was conjectured that scans of smaller tumors might include a higher percentage of surrounding tissue than would scans of larger tumors, leading to greater heterogeneity of tissue within the scan, which would be evidenced by a higher level of variability.
As the transducers all had different bandwidths, 2 frequency ranges were selected for the subsequent analyses that allowed for all of the larger range of frequencies to be covered and to ensure all transducers were included. The lower frequency range (3-8.5 MHz) included data from the Ultrasonix and Siemens transducers, and the higher frequency range (8.5-13.5 MHz) included data from the VisualSonics transducers.
To provide an estimate of the difference in magnitude of the BSC estimates between different imaging systems and transducers, a root mean squared error (RMSE) of the logarithm of the BSC-versus-frequency curves between and within systems was calculated. This process enabled an assessment of how the system variation compared to the inherent replication noise level. To calculate the RMSE, the BSC for each transducer was averaged over all slices and at each frequency, after interpolating to the same frequency steps. The logarithm was taken of the BSC, and differences were calculated for all pairs of transducers in the frequency band. The RMSE was then calculated by squaring the difference at each frequency step, averaging across frequencies in the frequency band, and obtaining the root of the resulting error. The maximum RMSEs within and between systems were plotted as a function of tumor volume for each tumor type. For the higher frequency range, only a "within-system" RMSE was calculated. To formally test the capability of the BSC curve to detect tumor differences a functional ANOVA test 27 for tumor effect was conducted using the BSC data from each transducer frequency range. Statistical significance was computed via bootstrap resampling. 26 The functional signal-to-noise ratio (SNR) for tumor effect was computed 23 for each transducer. To test for possible transducer differences, functional ANOVA was conducted within tumor types and across transducers that covered the lower and higher frequency ranges. Functional ANOVA and functional SNR analyses were necessary because the BSC data consisted of frequency-dependent curves rather than single values; hence, traditional ANOVA methods did not apply to these data. 28 
Statistical Analysis Results
The Std values of the log-BSC across slices for each transducer and each tumor are plotted in Figure A2a The RMSE between the log-scaled BSC curves was computed for each pair of transducers over each of the frequency ranges. The results are summarized in Figure A3 , showing the RMSE of the log-BSC for the comparison of both transducers within the same imaging system and between imaging systems over both the low and high frequency ranges used. The highest maximum RMSE values decreased with increased tumor size; ie, a substantial drop in the within-system RMSE is observed around 80 mm 3 , with a similar trend but less substantial decrease observed for the between-system RMSE.
The functional ANOVA and functional SNR results for detection of tumor differences are summarized in Table A1 .
There were statistically significant differences between MAT and 4T1 tumors for both VisualSonics transducers and a close P value (.061) for the Siemens 9L4 transducer. The result indicates that the VisualSonics MS200 and MS400 transducers could differentiate between the MAT and 4T1 tumors. Additionally, no statistically significant differences were found for the detection of transducer differences from the functional ANOVA summarized in Table A2 . These results indicate that there were no statistically significant detected differences between transducers in a given frequency range. Comparison of functional SNR values in Table A1 versus Table A2 also indicated that the signal for tumor differences was considerably larger than the signal for transducer differences, the latter of which was not statistically significant. Figure A3 . The maximum RMSE of the log-BSC for each tumor is plotted versus the tumor volume. The BSC unit is cm -1 Sr -1 . The betweensystem RMSE is plotted in blue, and the within-system (transducers from the same imaging system) RMSE is plotted in red.
